Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-Lumefantrine (6-Dose) in African Children with Malaria
NCT00709969Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2002
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of artemether + lumefantrine in Plasmodium falciparum malaria, sponsored by Novartis. Primary endpoint: Adverse events, SAEs at 28 days. Started Jul 2002; status: completed.
02
Drugs
artemether + lumefantrine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT00709969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00709969.